Multi-year funding aims to accelerate model for affordable cancer drug development
NP2, a nonprofit pharmaceutical organization and social enterprise, announces a major achievement: a seven-figure philanthropic commitment from Lyda Hill Philanthropies, with milestone-based funding provided over two years. The funding is designed to catalyze critical stages of NP2’s pipeline, including drug development, manufacturing, regulatory approval, and initial commercialization. The contribution marks a pivotal step in NP2’s growth, providing essential leverage as the organization advances toward full-scale market entry while continuing to raise additional capital to fund its first United States-manufactured, lower-priced, lifesaving oncology drug.
At the core of NP2’s mission is a simple but ambitious principle: patients over profit. According to the American Association for Cancer Research, more than half of cancer patients in the United States experience financial hardship due to the cost of care, often forcing difficult choices between treatment and basic needs. NP2 was founded to change that reality by rethinking how essential medicines are developed, manufactured, and priced.
NP2 focuses on reducing the cost of critical medicines and ensuring a safe and steady supply at a lower cost for healthcare systems and patients alike. The nonprofit’s initial pipeline will focus on high-demand cancer drugs that have experienced price fluctuations or supply chain disruptions. Unlike traditional for-profit pharmaceutical models, NP2 reinvests proceeds directly back into its mission to expand its pipeline of lower-priced life-saving generics, creating a self-sustaining engine for both affordability and innovation. NP2’s drug program is designed to reduce dependence on fragmented international supply chains and ensure a more resilient, transparent, and dependable pathway for essential medicines to reach patients.
“The landmark funding from Lyda Hill Philanthropies is a powerful validation that a different model is not only possible, but necessary,” said Terri Miller, Executive Director of NP2. “We are deeply grateful for their partnership and belief in our mission. NP2 exists to challenge the systemic issue of life-saving medicines being out of reach for too many patients. We are building a model in which affordability and a reliable supply chain are integrated from the start, and where patients come before profit. This milestone allows us to jumpstart the process, but we are just getting started.”
As a nonprofit social enterprise, NP2 brings together a small but highly strategic and dedicated network of scientists, attorneys, physicians, entrepreneurs, and pharmaceutical industry experts with over 150 years of combined experience, a majority of whom contribute their skills on a pro bono basis. The organization is actively collaborating with a growing ecosystem of partners to accelerate development while maintaining rigorous standards for safety, efficacy, and accessibility.
“NP2 represents the kind of mission-driven innovation Lyda Hill Philanthropies is committed to advancing,” said Lyda Hill, Founder of Lyda Hill Philanthropies. “We applaud NP2 for catalyzing meaningful change in drug affordability and look forward to seeing the long-term impact of this work on patients and the broader healthcare system.”
By combining scientific rigor with a nonprofit mission structure, NP2 is positioning itself at the forefront of a growing movement to rethink how essential medicines are brought to market and who ultimately benefits from them.
Source: Press release
